{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T02:00:24Z","timestamp":1794448824842,"version":"4.9.1"},"reference-count":38,"publisher":"Japanese Society of Internal Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,3,15]]},"DOI":"10.2169\/internalmedicine.5856-25","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T22:07:25Z","timestamp":1755122845000},"page":"802-809","source":"Crossref","is-referenced-by-count":4,"title":["Effect of Galcanezumab on PHQ-9 and GAD-7 in Patients with Migraine: A Real-world Study in Japan"],"prefix":"10.2169","volume":"65","author":[{"given":"Kota","family":"Oshima","sequence":"first","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"},{"name":"Department of Neuropsychiatry, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuna","family":"Hattori","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Ihara","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narumi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Takemura","sequence":"additional","affiliation":[{"name":"Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Ishizuchi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Sekiguchi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Nakahara","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsubasa","family":"Takizawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Breslau N, Davis GC, Andreski P. Migraine, psychiatric disorders, and suicide attempts: an epidemiologic study of young adults. Psychiatry Res 37: 11-23, 1991.","DOI":"10.1016\/0165-1781(91)90102-U"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, burden, and comorbidity. Neurol Clin 37: 631-649, 2019.","DOI":"10.1016\/j.ncl.2019.06.001"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Jette N, Patten S, Williams J, Becker W, Wiebe S. Comorbidity of migraine and psychiatric disorders - a national population-based study. Headache 48: 501-516, 2008.","DOI":"10.1111\/j.1526-4610.2007.00993.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Lant\u00e9ri-Minet M, Radat F, Chautard MH, Lucas C. Anxiety and depression associated with migraine: influence on migraine subjects&apos; disability and quality of life, and acute migraine management. Pain 118: 319-326, 2005.","DOI":"10.1016\/j.pain.2005.09.010"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Lucas C, Lant\u00e9ri-Minet M, Massiou H, et al. The GRIM2005 study of migraine consultation in France II. Psychological factors associated with treatment response to acute headache therapy and satisfaction in migraine. Cephalalgia 27: 1398-1407, 2007.","DOI":"10.1111\/j.1468-2982.2007.01446.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Schiano di Cola F, Caratozzolo S, Liberini P, Rao R, Padovani A. Response predictors in chronic migraine: medication overuse and depressive symptoms negatively impact onabotulinumtoxin - a treatment. Front Neurol 10: 678, 2019.","DOI":"10.3389\/fneur.2019.00678"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Sacco S, Amin FM, Ashina M, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain 23: 67, 2022.","DOI":"10.1186\/s10194-022-01431-x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Takizawa T, Ohtani S, Watanabe N, et al. Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis. BMC Neurol 22: 512, 2022.","DOI":"10.1186\/s12883-022-03041-1"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Suzuki K, Suzuki S, Shiina T, et al. Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: a 12-month, single-center, observational real-world study in Japan. Cephalalgia 43: 3331024231177649, 2023.","DOI":"10.1177\/03331024231177649"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Ohtani S, Watanabe N, Ihara K, et al. Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study. BMC Neurol 23: 404, 2023.","DOI":"10.1186\/s12883-023-03449-3"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Takizawa T, Ihara K, Watanabe N, et al. CGRP-monoclonal antibodies in Japan: insights from an online survey of physician members of the Japanese headache society. J Headache Pain 25: 39, 2024.","DOI":"10.1186\/s10194-024-01737-y"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ihara K, Takahashi N, Ohtani S, et al. Real-world efficacy of erenumab on migraine-associated symptoms and patient-reported satisfaction levels: a retrospective study in Japan. Intern Med 2024.","DOI":"10.2169\/internalmedicine.4037-24"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Talbot J, Stuckey R, Crawford L, Weatherby S, Mullin S. Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment - real world outcomes. J Headache Pain 22: 5, 2021.","DOI":"10.1186\/s10194-020-01214-2"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394: 1030-1040, 2019.","DOI":"10.1016\/S0140-6736(19)31946-4"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Maizels M, Buse DC, Jedynak J, Hand AL, Ford J, Detke H. Changes in depression and anxiety in a randomized, double-blind, placebo-controlled study of galcanezumab in adults with treatment-resistant migraine: results from the CONQUER study (1383). Neurology 94: 1383, 2020.","DOI":"10.1212\/WNL.94.15_supplement.1383"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Lipton RB, Cohen JM, Galic M, et al. Effects of fremanezumab in patients with chronic migraine and comorbid depression: subgroup analysis of the randomized HALO CM study. Headache 61: 662-672, 2021.","DOI":"10.1111\/head.14097"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Silvestro M, Tessitore A, Orologio I, et al. Galcanezumab effect on &quot;whole pain burden&quot; and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience. J Headache Pain 23: 69, 2022.","DOI":"10.1186\/s10194-022-01436-6"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Russo A, Silvestro M, Scotto Di, Clemente F, et al. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain 21: 69, 2020.","DOI":"10.1186\/s10194-020-01143-0"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ihara K, Ohtani S, Watanabe N, et al. Switching between anti-calcitonin gene-related peptide monoclonal antibodies: a comparison of monthly and quarterly dosing. J Neurol Sci 453: 120811, 2023.","DOI":"10.1016\/j.jns.2023.120811"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Ihara K, Ohtani S, Watanabe N, et al. Response to letter: &quot;Switching from calcitonin gene-related peptide monoclonal antibody monthly to fremanezumab quarterly based on the patient&apos;s preferred dosing schedule&quot; by Suzuki et al. J Neurol Sci 455: 122785, 2023.","DOI":"10.1016\/j.jns.2023.122785"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Oshima K, Ihara K, Watanabe N, et al. Efficacy and safety of switching between anti-CGRP monoclonal antibodies: a detailed monthly and long-term follow-up study and literature review. Intern Med 2025.","DOI":"10.2169\/internalmedicine.4360-24"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Muramatsu K, Miyaoka H, Kamijima K, et al. Performance of the Japanese version of the Patient Health Questionnaire-9 (J-PHQ-9) for depression in primary care. Gen Hosp Psychiatry 52: 64-69, 2018.","DOI":"10.1016\/j.genhosppsych.2018.03.007"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Doi S, Ito M, Takebayashi Y, Muramatsu K, Horikoshi M. Factorial validity and invariance of the 7-item generalized anxiety disorder scale (GAD-7) among populations with and without self-reported psychiatric diagnostic status. Front Psychol 9: 1741, 2018.","DOI":"10.3389\/fpsyg.2018.01741"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Muramatsu K, Maeda S, Miyaoka H, et al. Diagnostic performance of the Japanese version of the GAD-7 in primary care and comparing its accuracy with other language versions. Med Res Arch 13: 2025.","DOI":"10.18103\/mra.v13i1.6247"},{"key":"25","unstructured":"25. Tseng VWS, Tharp JA, Reiter JE, et al. Identifying a stable and generalizable factor structure of major depressive disorder across three large longitudinal cohorts. Psychiatry Res 333: 115702, 2024."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. L\u00f6we B, Un\u00fctzer J, Callahan CM, Perkins AJ, Kroenke K. Monitoring depression treatment outcomes with the Patient Health Questionnaire-9. Med Care 42: 1194-1201, 2004.","DOI":"10.1097\/00005650-200412000-00006"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Toussaint A, H\u00fcsing P, Gumz A, et al. Sensitivity to change and minimal clinically important difference of the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7). J Affect Disord 265: 395-401, 2020.","DOI":"10.1016\/j.jad.2020.01.032"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. de Vries Lentsch S, van der Arend BWH, de Boer I, van Zwet EW, MaassenVanDenBrink A, Terwindt GM. Depression and treatment with anti-calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies for migraine. Eur J Neurol 31: e16106, 2024.","DOI":"10.1111\/ene.16106"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Torres-Ferr\u00fas M, Gallardo VJ, Alpuente A, Caronna E, Gin\u00e9-Cipr\u00e9s E, Pozo-Rosich P. Improvement of migraine depressive symptoms is not related to headache frequency: exploring the impact of anti-CGRP therapies. Cephalalgia 44: 3331024231222923, 2024.","DOI":"10.1177\/03331024231222923"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Math\u00e9 AA, Agren H, Lindstr\u00f6m L, Theodorsson E. Increased concentration of calcitonin gene-related peptide in cerebrospinal fluid of depressed patients. A possible trait marker of major depressive disorder. Neuroscience 182: 138-142, 1994.","DOI":"10.1016\/0304-3940(94)90782-X"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31. Ashina M, Bendtsen L, Jensen R, Schifter S, Olesen J. Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks. Pain 86: 133-138, 2000.","DOI":"10.1016\/S0304-3959(00)00232-3"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. van Dongen RM, Zielman R, Noga M, et al. Migraine biomarkers in cerebrospinal fluid: a systematic review and meta-analysis. Cephalalgia 37: 49-63, 2017.","DOI":"10.1177\/0333102415625614"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Gungor NZ, Pare D. CGRP inhibits neurons of the bed nucleus of the stria terminalis: implications for the regulation of fear and anxiety. J Neurosci 34: 60-65, 2014.","DOI":"10.1523\/JNEUROSCI.3473-13.2014"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Hashikawa-Hobara N, Fujiwara K, Hashikawa N. CGRP causes anxiety via HP1\u03b3-KLF11-MAOB pathway and dopamine in the dorsal hippocampus. Commun Biol 7: 322, 2024.","DOI":"10.1038\/s42003-024-05937-9"},{"key":"35","doi-asserted-by":"publisher","unstructured":"35. Giannakopoulou O, Lin K, Meng X, et al. The genetic architecture of depression in individuals of East Asian ancestry: a genome-wide association study. JAMA Psychiatry 78: 1258-1269, 2021.","DOI":"10.1001\/jamapsychiatry.2021.2099"},{"key":"36","doi-asserted-by":"publisher","unstructured":"36. Peng KP, Wang SJ. Epidemiology of headache disorders in the Asia-Pacific region. Headache 54: 610-618, 2014.","DOI":"10.1111\/head.12328"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Schur EA, Noonan C, Buchwald D, Goldberg J, Afari N. A twin study of depression and migraine: evidence for a shared genetic vulnerability. Headache 49: 1493-1502, 2009.","DOI":"10.1111\/j.1526-4610.2009.01425.x"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Stam AH, de Vries B, Janssens ACJW, Vanmolkot KRJ, Aulchenko YS, Henneman P. Shared genetic factors in migraine and depression. Neurology 74: 288-294, 2010.","DOI":"10.1212\/WNL.0b013e3181cbcd19"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/6\/65_5856-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T03:33:36Z","timestamp":1774064016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/6\/65_5856-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,15]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5856-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,15]]},"article-number":"5856-25"}}